Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II nivolumab in platinum-resistant mismatch repair deficient germ cell tumors
2017-000589-31Phase 2Terminated
- Sponsor
- Campania Society of ImmunoTherapy of Cancer
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in germ cell tumor (GCT), sponsored by Campania Society of ImmunoTherapy of Cancer. Primary endpoint: Disease Control Rate (DCR) by RECIST v1.1. Started Jun 2021; status: terminated.
02
Drugs
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on 2017-000589-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000589-31.